Glaukos (NYSE:GKOS) said yesterday that closed the nearly $3 million plus milestones to acquire former subsidiary Dose Medical and its drug-delivery technology for treating retinal diseases.
Sam Clemente, Calif.-based Glaukos spun Dose out as a standalone company in 2010, but paid $26 million in July 2015 for Dose Medical’s glaucoma assets.
Get the full story at our sister site, Drug Delivery Business News